E Fund Management (Hong Kong) Co., Ltd. Bei Gene, Ltd. Transaction History

E Fund Management (Hong Kong) Co., Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 24, 2022	SELL	$131.8 - $202.24 $34,004 - $52,177	-258 Reduced 0.8%	31,961 $4.31 Million
Q2 2022 Jul 13, 2022	BUY	$121.11 - $216.05 $571,396 - $1.02 Million	4,718 Added 17.16%	32,219 $5.22 Million
Q1 2022 Apr 12, 2022	BUY	$146.52 - $269.56 $2.33 Million - $4.29 Million	15,929 Added 137.65%	27,501 $5.07 Million
Q4 2021 Feb 07, 2022	SELL	$248.56 - $389.34 $43,498 - $68,134	-175 Reduced 1.49%	11,572 $3.14 Million
Q2 2021 Jul 27, 2021	SELL	$292.75 - $367.01 $127,053 - $159,282	-434 Reduced 3.56%	11,747 $4.03 Million
Q1 2021 Apr 13, 2021	BUY	$260.64 - $382.12 $47,175 - $69,163	181 Added 1.51%	12,181 $4.24 Million
Q4 2020 Jan 05, 2021	BUY	$221.31 - $316.61 $2.66 Million - $3.8 Million	12,000 New	12,000 $3.1 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of E Fund Management (Hong Kong) Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management (Hong Kong) Co., Ltd. with notifications on news.